You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. ACE Booster

    SBC: GLOYER-TAYLOR LABORATORIES INC            Topic: T102

    GTL has been developing three transformational technologies that have the capability to disrupt the traditional launch vehicle paradigm. BHL composite cryotank technology provides a four times improvement over large Al-Li tanks, offering a 6 percentage point improvement in stage PMF. Superior Stability Engine is an innovative liquid rocket engine configured to maximize combustion stability margi ...

    STTR Phase I 2014 National Aeronautics and Space Administration
  2. ACE Booster

    SBC: GLOYER-TAYLOR LABORATORIES INC            Topic: T102

    GTL has been developing a suite of transformational technologies that have the capability to disrupt the traditional launch vehicle paradigm. BHL composite cryotank technology provides a four times improvement over large aluminum iso-grid tanks, offering a 6 percentage point improvement in small stage PMF. Superior Stability Engine is an innovative liquid rocket engine configured to maximize comb ...

    STTR Phase II 2015 National Aeronautics and Space Administration
  3. ACE Booster

    SBC: GLOYER-TAYLOR LABORATORIES INC            Topic: T1

    GTL has been developing a suite of transformational technologies that have the capability to disrupt the traditional launch vehicle paradigm.BHL composite cryotank technology provides a four times improvement over large aluminum iso-grid tanks, offering a 6 percentage point improvement in small stage PMF. Superior Stability Engine is an innovative liquid rocket engine configured to maximize combus ...

    STTR Phase II 2019 National Aeronautics and Space Administration
  4. Acne Vaccines Targeting a Surface Sialidase and a Secreted CAMP Factor Toxin

    SBC: VAXIN INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Propionibacterium acnes (P. acnes) is most notably recognized for its role in acne vulgaris, the most common skin disease, affecting 85-100% of the population at some point in their lives. Current treatments for vulgari s acne using isotretinoin (13-cis-retinoic acid) or antibiotics can have many undesirable effects, including depression, teratogenicity, hormon ...

    STTR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
  5. Active Radiation Shield

    SBC: GLOYER-TAYLOR LABORATORIES INC            Topic: T301

    DEC-Shield technology offers the means to generate electric power from cosmic radiation sources and fuse dissimilar systems and functionality into a structural component to create a Multi-functional Structure (MFS). DEC-Shield integrated into MFS technology can be used to generate electric power and provide radiation protection in a space vehicle; even maximizing that protection by spreading the ...

    STTR Phase I 2016 National Aeronautics and Space Administration
  6. Active Radiation Shield

    SBC: GLOYER-TAYLOR LABORATORIES INC            Topic: T301

    In the Phase I effort, Gloyer-Taylor Laboratories LLC (GTL) verified the feasibility of generating power from space particle radiation. This effort successfully demonstrated electrical power production from a particle radiation source using an initial proof-of-concept device. The effort also identified a second approach that has the potential for even better power generation and offers enhanced ...

    STTR Phase II 2017 National Aeronautics and Space Administration
  7. Acute-infarct selective cardiac MRI contrast agent

    SBC: ELGAVISH PARAMAGNETICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Reliable diagnostic differentiation between acute and chronic myocardial infarcts would be of great benefit for cardiac surgeons and interventional cardiologists. Such differentiation could be used to make decisions about which vessels and in what order would be reopened or bypassed. MRI is an intrinsically noninvasive diagnostic tool and the Delayed Enhancemen ...

    STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  8. Acute-infarct selective cardiac MRI contrast agent

    SBC: ELGAVISH PARAMAGNETICS, INC.            Topic: NHLBI

    DESCRIPTION provided by applicant The overall goal of this project is to demonstrate the ability of our acute myocardial infarct selective paramagnetic contrast agent Gadolinium ABE DTTA to differentiate between acute and chronic infarcts in a reliable manner using contrast enhanced magnetic resonance imaging ceMRI In our Phase I data we have shown that Gd ABE DTTA exclusively highlight ...

    STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  9. Additive Manufacture of Refractory Metal Propulsion Components

    SBC: GEOPLASMA LLC            Topic: T9

    Niobium alloy (C-103) reaction control system (RCS) chambers have been used on numerous NASA programs. However at elevated temperatures, the strength of C-103 decreases significantly. Higher strength niobium alloys have been developed, but these alloys lack the formability of C-103. Recently, Additive Manufacture (AM) of niobium and C-103 has been demonstrated using powder bed electron beam me ...

    STTR Phase I 2018 National Aeronautics and Space Administration
  10. Adenovirus vectored vaccines for Alzheimer's disease

    SBC: VAXIN INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Alzheimer disease (AD) is the most common neurodegenerative disease in the elderly. To date, no satisfactory treatment is available for AD. One of the pathological hallmarks of AD is deposits of amyloid protein (Aa) in neuritic plaques and cerebral vessels. Increasing lines of evidence support the notion that Aa and its precursor (APP) play pathogenetic roles i ...

    STTR Phase I 2007 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government